Phosphorylated tau 217 (pTau 217), Plasma, (Quest AD-Detect®, ALZpath pTau217)
Alzheimer’s disease (AD) is a complex, progressive neurodegenerative disorder characterized by memory loss and impaired cognitive function. The underlying pathology is believed to involve the deposition of amyloid plaques and neurofibrillary tangles, which consist of fibrillar Aβ protein and hyperphosphorylated tau (τ) protein, respectively. These pathological changes can be assessed through biomarkers that provide a more specific evaluation of AD in living individuals. Traditionally, amyloid and tau pathologies have been measured using positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) analysis, both of which are integral in the diagnostic process and form the basis of the biological definition of AD. The International Working Group recommends combining these biomarker assessments with clinical evaluation for the diagnosis of AD. However, both PET and CSF assessments are invasive, costly, and not widely accessible.
Blood-based biomarkers offer a more accessible, less invasive alternative, allowing for earlier diagnosis or avoiding unnecessary PET or CSF procedures. One of the most promising blood-based biomarkers is tau protein phosphorylated at threonine 217 (p-tau217). Elevated levels of plasma p-tau217 are associated with AD in its mild cognitive impairment (MCI) and dementia stages and strongly correlate with the presence of Aβ and tau pathology as confirmed by PET and CSF assessments. Plasma p-tau217, in particular, shows a robust association with Aβ pathology, which is known to increase in the early stages of AD progression.
As a highly dynamic and specific biomarker for AD, plasma p-tau217 levels increase over time in Aβ-positive individuals, but not in those who are Aβ-negative. These levels rise across advancing stages of tau pathology, making plasma p-tau217 a strong predictor of cognitive decline and disease progression. In addition, increased baseline plasma p-tau217 levels are indicative of future cognitive impairment, and longitudinal increases are correlated with further cognitive decline. Importantly, plasma p-tau217 can distinguish AD from other neurodegenerative diseases, such as frontotemporal dementia, progressive supranuclear palsy, and Parkinson's disease.
- Aid in the diagnosis of Alzheimer's disease in adults with mild cognitive impairment or dementia
- Help to assess whether mild cognitive impairment or dementia is caused by Alzheimer's disease or other neurological cause
Normal plasma p-tau217 levels (≤0.15 pg/mL) are inconsistent with mild cognitive impairment and dementia caused by AD.
Increased plasma p-tau217 levels (>0.15 pg/mL) are consistent with mild cognitive impairment and dementia caused by AD. Consider follow-up biomarker assessment using PET or CSF analysis to confirm the presence of AD pathology.
Note: Plasma p-tau217 levels can be increased in those with chronic kidney disease or a history of myocardial infarction or stroke.
Normal plasma p-tau217 levels ≤0.15 pg/mL
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Plasma EDTA (lavender-top) tube.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- JAMA Neurol. 2024 Mar 1;81(3):255-263. [PMID: 38252443]
- Brain. 2020;143(11):3234-3241. [PMID: 33068398]
- JAMA Neurol. 2023 Apr 1;80(4):360-369. [PMID: 36745413]
- Alzheimer’s Dement. 2011;7(3):263-269. [PMID: 21514250]
- JAMA. 2020;324(8):772-781. [PMID: 32722745]
- Alzheimers Dement. 2023 Apr;19(4):1598-1695. [PMID: 36918389]
- medRxiv [Preprint]. 2023 Jul 12:2023.07.11.23292493. [PMID: 37502842]
- Lancet Neurol. 2021;20(6):484-496. [PMID: 33933186]